Catalyst Biosciences to Participate in Two Upcoming Investor Conferences
10 juin 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in fireside...
Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra
18 mai 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of...
Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit
13 mai 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update
06 mai 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021...
Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors
05 mai 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3...
Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology
19 avr. 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the publication of preclinical data from its study of CB 2679d-GT in...
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders
12 avr. 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S....
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
07 avr. 2021 16h05 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate...
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
04 mars 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year...
Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference
18 févr. 2021 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its executive management team will participate in a...